‘We’d like to think our problems are behind us’, says Keith Cornwell, the chairman who has returned to running this beleaguered management and IT consulting company following managing director Jonathan Broadhurst’s resignation in April due to ill health.
As trailed in earlier trading statements Cornwell, which provides advice and consulting to public and private sector clients across government, defence, health, and financial services, posted woeful interims to June with pre-tax profits of £969,000 giving way to losses of £476,000. Earnings of 4.2p slipped to a loss per share of 2.3p, and the interim dividend was skipped.
Turnover was up a decent 15.3% to £11.5m – organic growth, stripping out the disappointing Quantum Plus acquisition, was 8.6% – reflecting good customer base and client assignment growth. However after a good first quarter in which sales and profits were ahead of forecasts, the second quarter was marked by a dramatic downturn reversing all the earlier good work.
In April, there was a sharp slowdown in revenues from the core public sector market, with the changeover to the new government financial year causing major ‘slippage’ in clients giving the go-ahead for projects. This seriously hit Cornwell’s gross margins, with consultant utilisation levels lower than budgeted. ‘The work wasn’t there in April, May and June’, explained Cornwell, 'and our consultants were stuck on the bench’.
On the plus side, a strategic review has completed, some £1m of annualised savings should come through, and the chairman has a cautious eye on rising utilisation rates and underlying profits. Demand generally remains strong in the public sector, though competition in the private sphere remains cut throat with clients under pressure to reign in consultant spend. Until trading and management stability returns however, we urge investors to give the depressed shares a wide berth.
Market cap: £7.05m
PE Forecast: n/a
Share price: 40p
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.